Evidence map›Paper›PMID 39125675›Full record

ArticleInternational journal of molecular sciences2024

MMP-14 Exhibits Greater Expression, Content and Activity Compared to MMP-15 in Human Renal Carcinoma.

Grzegorz Młynarczyk, Anna Tokarzewicz, Monika Gudowska-Sawczuk, Barbara Mroczko, Vojtěch Novák, Adam Novák, Przemysław Mitura, Lech Romanowicz

Abstract readComparative Study
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Grzegorz MłynarczykDepartment of Urology, Medical University of Białystok, 15-276 Białystok, Poland.
Anna TokarzewiczDepartment of Medical Biochemistry, Medical University of Białystok, ul. Mickiewicza 2, 15-089 Białystok, Poland.ORCID 0000-0001-9951-2433
Monika Gudowska-SawczukDepartment of Biochemical Diagnostics, Medical University of Białystok, 15-269 Białystok, Poland.ORCID 0000-0003-4854-7155
Barbara MroczkoDepartment of Biochemical Diagnostics, Medical University of Białystok, 15-269 Białystok, Poland.ORCID 0000-0002-4075-8479
Vojtěch NovákDepartment of Urology, Charles University and University Hospital Motol, 150 06 Praha, Czech Republic.
Adam NovákDepartment of Urology, Charles University and University Hospital Motol, 150 06 Praha, Czech Republic.
Przemysław MituraDepartment of Urology and Oncological Urology, Medical University of Lublin, 20-059 Lublin, Poland.
Lech RomanowiczDepartment of Medical Biochemistry, Medical University of Białystok, ul. Mickiewicza 2, 15-089 Białystok, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Membrane-type metalloproteinases (including MMP-14 and MMP-15) are enzymes involved in the degradation of extracellular matrix components. In cancer, they are involved in processes such as cellular invasion, angiogenesis and metastasis. Therefore, the aim of this study was to evaluate the expression, content and activity of MMP-14 and MMP-15 in human renal cell carcinoma. Samples of healthy kidney tissue (n = 20) and tissue from clear-cell kidney cancer (n = 20) were examined. The presence and contents of the MMPs were assessed using Western blot and ELISA techniques, respectively. Their activity-both actual and specific-was evaluated using fluorimetric analysis. Both control and cancer human kidney tissues contain MMP-14 and MMP-15 enzymes in the form of high-molecular-weight complexes. Moreover, these enzymes occur in both active and latent forms. Their content in cancer tissues is very similar, but with a noteworthy decrease in content with an increase in the kidney cancer grade for both membrane-type metalloproteinases. Even more notable is the highest content of the investigated enzymes represented by MMP-14 in the control tissues. Considering the actual and specific activity outcomes, MMP-14 dominates over MMP-15 in all of the investigated tissues. Nevertheless, we also noted a significant enhancement of the activity of both metalloproteinases with an increase in the grade of renal cancer. The expression and activity of both enzymes were detected in all examined renal cancer tissues. However, our findings suggest that transmembrane metalloproteinase 14 (MMP-14) plays a much more significant and essential role than MMP-15 in the studied renal carcinoma tissues. Therefore, it seems that MMP-14 could be a promising target in the diagnosis, prognosis and therapy of renal cell carcinoma.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMatrix Metalloproteinase 14Matrix Metalloproteinase 15AdultAgedFemaleHumansMaleMiddle AgedMatrix Metalloproteinase 14Matrix Metalloproteinase 15MMP14 protein, humanMMP15 protein, humancancerMMP-14MMP-15renal carcinomatransmembrane metalloproteinases

Identifiers

PMID39125675
PMCPMC11312297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.